Bridgefront Capital’s Arcus Biosciences RCUS Stock Holding History

Bridgefront Capital’s Portfolio RCUS Stock Details RCUS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-16,721	Closed	-$255K	–	682
2024 Q2	$255K	Buy	+16,721	New	+$270K	0.11%	345

Other funds holding RCUS

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Bridgefront Capital's RCUS Position: Q3 2024 in Review

Bridgefront Capital sold out of Arcus Biosciences (RCUS) in Q3 2024, closing a stake of 16,721 shares — an estimated $255K sold.

Bridgefront Capital first reported a position in RCUS in Q2 2024 and held it in 1 quarter. The position peaked at $255K in Q2 2024. 187 funds tracked by Wall St. Rank hold RCUS as of Q3 2024.

Bridgefront Capital reported no remaining Arcus Biosciences position as of Q3 2024 after selling out during the quarter.
Bridgefront Capital sold 16,721 Arcus Biosciences shares in Q3 2024, an estimated $255K.
Bridgefront Capital first reported a position in Arcus Biosciences in Q2 2024 and held it in 1 quarter.
Bridgefront Capital's Arcus Biosciences position peaked at $255K in Q2 2024.
187 funds tracked by Wall St. Rank held Arcus Biosciences as of Q3 2024.

Based on Bridgefront Capital's 13F filing for Q3 2024, filed 14 Nov 2024.